Across TCGA pan-cancer cohorts, POTEM Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated POTEM data layer compared with 13 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher POTEM Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated POTEM expression acts as an unfavorable survival marker.

BLCA, ACC, and COAD are the cancer types where POTEM Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	All	0.187	0.720	.002	24	view →
ACC	OS	Median	All	0.118	0.624	.038	6	view →
COAD	OS	Median	All	0.176	0.614	.047	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: POTEM tumor-vs-normal RNA expression · all POTEM data types